Selecting lncRNAs in gastric cancer cells for directed therapy with bioactive peptides and chemotherapy drugs

Abstract

Selecting lncRNAs for directed therapy with bioactive peptides and chemotherapy drugs may be an effective approach to treating gastric cancer (GC). We show genome-scale identification and characterization of differentially expressed lncRNAs in GC cells treated with a novel anti-cancer bioactive peptide (ACBP) and the chemotherapy drug oxaliplatin (ASLB). A total of 17,897 lncRNAs were identified through pairwise comparison, including 2,074 novel lncRNAs. Of those, 1,386 lncRNAs were differentially expressed (over 1.5-fold change vs. control, q-value < 0.05) in response to ACBP and ASLB treatment. These included 914 upregulated and 472 downregulated lincRNAs. Functional annotation of these lncRNAs through Kyoto Encyclopedia of Genes and Genome (KEGG) pathway analysis revealed they activate metabolic pathways and protein-binding processes. Moreover, suppression of the DNA replication process and upregulation of AMP-activated protein kinase (AMPK) signaling in MKN45 cells exposed to ACBP alone or in combination with ASLB was predicted by hierarchical clustering analysis. By providing new insight into the transcriptomic effects of ACBP and ASLB in GC cells, these results provide the first evidence of ACBP inhibition of lincRNAs and may provide new mechanisms of action for ACBP and ASLB.

iTRAQ‑based proteomics analysis of the therapeutic effects of combined anticancer bioactive peptides and oxaliplatin on gastric cancer cells

“…Furthermore, the ACBP treatment group exhibited significant differences in the regulatory mechanisms of gastric cancer cells compared with the OXA treatment group. The enrichment results of the AMPK metabolic pathway were consistent with those of lncRNA in MKN-45 cells treated with ACBP-OXA (20), suggesting a close relationship between the two. The AMPK signaling pathway mainly regulates cell metabolism and plays a key role in the regulation of cell energy homeostasis.…”

“…Thus, current clinical research has been focusing on finding novel anticancer drugs with higher efficiency, lower toxicity and improved targeting ability. Previous studies have reported that ACBP combined with chemotherapy drugs (e.g., cisplatin and OXA) can inhibit the proliferation of MKN-45 cells, promote apoptosis and induce G2/M phase arrest (13,20). However, the mechanisms underlying the inhibitory effects of ACBP and chemotherapeutic drugs on cell growth remain largely unclear.…”

“…Extraction and purification of bioactive peptides were performed as previously reported (20). Additionally, the optimal concentration of 20 µg/ml bioactive peptides was determined and selected for the treatment of MKN-45 cells (10,11).…”

“…PBS is a phosphate buffer, which acts as a dissolving protective agent, does not affect cell growth and causes no damage to cells (11,21,22). After 36 h of incubation with all three treatments, the cells were collected for further analysis (13,20,23). All experiments were performed in triplicate.…”

A Four-Methylated lncRNAs-Based Prognostic Signature for Hepatocellular Carcinoma

“…Huang’s et al, study found that lncRNA LINC01269 may have a very important biological function, which is related to the OS rate and disease-free survival rate of patients with esophageal squamous cell carcinoma [ 41 ]. Han’s et al, study found that LINC01183 was the 10 most downregulated lncRNAs in gastric cancer cells [ 42 ]. In addition, The LncRNA and Disease Database (version 2.0) predicts that LINC01164 and LINC01269 are associated with a variety of cancers, such as non-small cell lung cancer and gastric cancer.…”